LEN, a multikinase inhibitor of VEGF receptors 1-3, FGF receptors 1-4, platelet-derived growth factor receptor-a, RET, and KIT, could suppress tumor angiogenesis and antitumor immunity in tumor microenvironments, which would enhance the effect of PD-1 antibodies and TACE (30, 34). This evidence concerns the gene RET and neoplasm.